Perceptive Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Perceptive Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-501,509	Closed	-$23.1M	–	125
2022 Q1	$23.1M	Buy	501,509 +70,965	+16%	+$3.83M	0.46%	51
2021 Q4	$36.2M	Buy	+430,544	New	+$33.3M	0.56%	47
2021 Q1	–	Sell	-1,050,003	Closed	-$54.5M	–	165
2020 Q4	$54.5M	Hold	1,050,003	–	–	0.59%	41
2020 Q3	$34.3M	Hold	1,050,003	–	–	0.5%	53
2020 Q2	$45.8M	Buy	+1,050,003	New	+$40.3M	0.74%	35

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Perceptive Advisors's ZNTL Position: Q2 2022 in Review

Perceptive Advisors sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2022, closing a stake of 501,509 shares — an estimated $23.1M sold.

Perceptive Advisors first reported a position in ZNTL in Q2 2020 and held it in 5 quarters. The position peaked at $54.5M in Q4 2020. 122 funds tracked by Wall St. Rank hold ZNTL as of Q2 2022.

Perceptive Advisors reported no remaining Zentalis Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Perceptive Advisors sold 501,509 Zentalis Pharmaceuticals shares in Q2 2022, an estimated $23.1M.
Perceptive Advisors first reported a position in Zentalis Pharmaceuticals in Q2 2020 and held it in 5 quarters.
Perceptive Advisors's Zentalis Pharmaceuticals position peaked at $54.5M in Q4 2020.
122 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2022.

Based on Perceptive Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.